An introduction to articles published in this issue is presented including an article on the issues related to the current and future status of erithropoisis-stimulating agent (ESA) treatment, another on hyperparathyroidism and an article on the significance of a bioimpedance analysis-derived extracellular mass/body cell mass ratio in peritoneal dialysis patients.